摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

16-triphenylmethoxy-1-hexadecanol | 745073-18-1

中文名称
——
中文别名
——
英文名称
16-triphenylmethoxy-1-hexadecanol
英文别名
16-(trityloxy)-1-hexadecanol;16-Trityloxyhexadecan-1-ol
16-triphenylmethoxy-1-hexadecanol化学式
CAS
745073-18-1
化学式
C35H48O2
mdl
——
分子量
500.765
InChiKey
QWHLZJYCQVXHOA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    593.4±45.0 °C(Predicted)
  • 密度:
    0.999±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    10.9
  • 重原子数:
    37
  • 可旋转键数:
    20
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.49
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    16-triphenylmethoxy-1-hexadecanol重铬酸吡啶甲酸 、 ammonium cerium(IV) nitrate 、 pyridinium chloroformate 、 4 A molecular sieve 、 甲基磺酰氯三乙胺lithium hexamethyldisilazane 作用下, 以 四氢呋喃乙醚二氯甲烷N,N-二甲基甲酰胺乙腈 为溶剂, 反应 34.0h, 生成 5-(benzyloxy)methyl-3-[(E)-16-carboxypentadecylidene]-5-hydroxymethyltetrahydro-2-furanone
    参考文献:
    名称:
    Macrocyclic Diacylglycerol-bis-lactones as Conformationally Constrained Analogues of Diacylglycerol-lactones. Interactions with Protein Kinase C
    摘要:
    A series of macrocyclic diacylglycerol (DAG)-bis-lactones were investigated as extreme conformationally constrained analogues of DAG-lactones in order to seek more potent protein kinase C (PKC) ligands with higher binding affinities and less lipophilicity than previous compounds. The additional constraint achieved the desired objective as exemplified by the macrocyclic DAG-bis-lactone 57, which exhibited a 6-fold higher binding affinity for PKCalpha (K-i = 6.07 nM) than the corresponding nonmacrocyclic 3-alkylidene DAG-lactone 6. A structure-activity relationship (SAR) analysis of the macrocyclic DAG-bis-lactones demonstrated a parabolic relationship between activity and lipophilicity, as well as a predilection for the Z-alkylidene isomers as the preferred ligands. Molecular docking studies revealed that macrocyclic DAG-bis-lactone 57 bound to the C1b domain of PKCalpha exclusively in the sn-1 binding mode in contrast to DAG-lactone 6, which showed both sn-1 and sn-2 binding modes. It is proposed that the high potency displayed by these macrocyclic DAG-bis-lactones results from a set of more favorable hydrogen bonding and hydrophobic interactions with PKCalpha as well as from a reduced entropy penalty due to conformational restriction.
    DOI:
    10.1021/jm0497747
  • 作为产物:
    描述:
    16-羟基棕榈酸 在 lithium aluminium tetrahydride 、 硫酸三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 2.0h, 生成 16-triphenylmethoxy-1-hexadecanol
    参考文献:
    名称:
    [EN] ENDOSOMOLYTIC AGENTS FOR GENE THERAPY
    [FR] AGENTS ENDOSOMOLYTIQUES POUR THÉRAPIE GÉNIQUE
    摘要:
    式(I)的化合物,其中Ar是一种芳基,可选择性地进一步取代为一个或多个基团R3;A是一个亲脂性、疏水性的基团;R1是一个磷酸二酯、磷酸三酯、硫醚或酰胺基团;X是一个未取代或取代的C6到C24烷基或烯基基团,该基团可被一个或多个-NR9-、-O-或-S-键所中断;R2是-YC(R4)(R5)CO2R6;以及其药学上可接受的盐或溶剂化合物,可用作内体溶解剂,特别用于传递在基因治疗中有用的核酸。
    公开号:
    WO2018060280A1
点击查看最新优质反应信息

文献信息

  • Endosomolytic agents for gene therapy
    申请人:UCB Biopharma SRL
    公开号:US10842884B2
    公开(公告)日:2020-11-24
    Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more —NR9—, —O— or —S— linkages, R2 is —YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
    式(I)化合物,其中 Ar 是可选被一个或多个基团 R3 进一步取代的芳基;A 是亲脂疏水分子;R1 是膦二酯、膦三酯、硫醚或酰胺基团;X 是未取代或取代的 C6 至 C24 亚烷基或烯基,该亚烷基或烯基任选被一个或多个 -NR9-、-O- 或 -S- 连接打断,R2 是 -YC(R4)(R5)CO2R6;其药学上可接受的盐或溶液可用作内溶酶体剂,特别是用于递送基因治疗中有用的核酸。
  • ENDOSOMOLYTIC AGENTS FOR GENE THERAPY
    申请人:UCB Biopharma SRL
    公开号:EP3519423B1
    公开(公告)日:2021-04-07
  • Endosomolytic Agents for Gene Therapy
    申请人:UCB Biopharma SPRL
    公开号:US20190298859A1
    公开(公告)日:2019-10-03
    Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R 3 ; A is a lipophilic, hydrophobic moiety; R 1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C 6 to C 24 alkylene or alkenylene group, which is optionally interrupted by one or more —NR 9 —, —O— or —S— linkages, R 2 is —YC(R 4 )(R 5 )CO 2 R 6 ; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
  • [EN] ENDOSOMOLYTIC AGENTS FOR GENE THERAPY<br/>[FR] AGENTS ENDOSOMOLYTIQUES POUR THÉRAPIE GÉNIQUE
    申请人:UCB BIOPHARMA SPRL
    公开号:WO2018060280A1
    公开(公告)日:2018-04-05
    Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more -NR9-, -O- or -S- linkages, R2 is -YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
    式(I)的化合物,其中Ar是一种芳基,可选择性地进一步取代为一个或多个基团R3;A是一个亲脂性、疏水性的基团;R1是一个磷酸二酯、磷酸三酯、硫醚或酰胺基团;X是一个未取代或取代的C6到C24烷基或烯基基团,该基团可被一个或多个-NR9-、-O-或-S-键所中断;R2是-YC(R4)(R5)CO2R6;以及其药学上可接受的盐或溶剂化合物,可用作内体溶解剂,特别用于传递在基因治疗中有用的核酸。
  • Macrocyclic Diacylglycerol-bis-lactones as Conformationally Constrained Analogues of Diacylglycerol-lactones. Interactions with Protein Kinase C
    作者:Ji-Hye Kang、Su Yeon Kim、Jeewoo Lee、Victor E. Marquez、Nancy E. Lewin、Larry V. Pearce、Peter M. Blumberg
    DOI:10.1021/jm0497747
    日期:2004.7.1
    A series of macrocyclic diacylglycerol (DAG)-bis-lactones were investigated as extreme conformationally constrained analogues of DAG-lactones in order to seek more potent protein kinase C (PKC) ligands with higher binding affinities and less lipophilicity than previous compounds. The additional constraint achieved the desired objective as exemplified by the macrocyclic DAG-bis-lactone 57, which exhibited a 6-fold higher binding affinity for PKCalpha (K-i = 6.07 nM) than the corresponding nonmacrocyclic 3-alkylidene DAG-lactone 6. A structure-activity relationship (SAR) analysis of the macrocyclic DAG-bis-lactones demonstrated a parabolic relationship between activity and lipophilicity, as well as a predilection for the Z-alkylidene isomers as the preferred ligands. Molecular docking studies revealed that macrocyclic DAG-bis-lactone 57 bound to the C1b domain of PKCalpha exclusively in the sn-1 binding mode in contrast to DAG-lactone 6, which showed both sn-1 and sn-2 binding modes. It is proposed that the high potency displayed by these macrocyclic DAG-bis-lactones results from a set of more favorable hydrogen bonding and hydrophobic interactions with PKCalpha as well as from a reduced entropy penalty due to conformational restriction.
查看更多

同类化合物

(3-三苯基甲氨基甲基)吡啶 非马沙坦杂质1 隐色甲紫-d6 隐色孔雀绿-d6 隐色孔雀绿 隐色乙基结晶紫 降钙素杂质10 酸性黄117 酸性蓝119 酚酞啉 酚酞二硫酸钾水合物 萘,1-甲氧基-3-甲基 苯酚,4-(1,1-二苯基丙基)- 苯甲醇,4-溴-a-(4-溴苯基)-a-苯基- 苯甲酸,4-(羟基二苯甲基)-,甲基酯 苯甲基N-[(2(三苯代甲基四唑-5-基-1,1联苯基-4-基]-甲基-2-氨基-3-甲基丁酸酯 苯基双-(对二乙氨基苯)甲烷 苯基二甲苯基甲烷 苯基二[2-甲基-4-(二乙基氨基)苯基]甲烷 苯基{二[4-(三氟甲基)苯基]}甲醇 苯基-二(2-羟基-5-氯苯基)甲烷 苄基2,3,4-三-O-苄基-6-O-三苯甲基-BETA-D-吡喃葡萄糖苷 苄基 5-氨基-5-脱氧-2,3-O-异亚丙基-6-O-三苯甲基呋喃己糖苷 苄基 2-乙酰氨基-2-脱氧-6-O-三苯基-甲基-alpha-D-吡喃葡萄糖苷 苄基 2,3-O-异亚丙基-6-三苯甲基-alpha-D-甘露呋喃糖 膦酸,1,2-乙二基二(磷羧基甲基)亚氨基-3,1-丙二基次氮基<三价氮基>二(亚甲基)四-,盐钠 脱氢奥美沙坦-2三苯甲基奥美沙坦脂 美托咪定杂质28 绿茶提取物茶多酚陕西龙孚 结晶紫 磷,三(4-甲氧苯基)甲基-,碘化 碱性蓝 硫代硫酸氢 S-[2-[(3,3,3-三苯基丙基)氨基]乙基]酯 盐酸三苯甲基肼 白孔雀石绿-d5 甲酮,(反-4-氨基-4-甲基环己基)-4-吗啉基- 甲基三苯基甲基醚 甲基6-O-(三苯基甲基)-ALPHA-D-吡喃甘露糖苷三苯甲酸酯 甲基3,4-O-异亚丙基-2-O-甲基-6-O-三苯甲基吡喃己糖苷 甲基2-甲基-N-{[4-(三氟甲基)苯基]氨基甲酰}丙氨酸酸酯 甲基2,3,4-三-O-苯甲酰基-6-O-三苯甲基-ALPHA-D-吡喃葡萄糖苷 甲基2,3,4-三-O-苄基-6-O-三苯甲基-ALPHA-D-吡喃葡萄糖苷 甲基2,3,4-三-O-(苯基甲基)-6-O-(三苯基甲基)-ALPHA-D-吡喃半乳糖苷 甲基-6-O-三苯基甲基-alpha-D-吡喃葡萄糖苷 甲基(1-trityl-1H-imidazol-4-yl)乙酸酯 甲基 2,3,4-三-O-苄基-6-O-三苯基甲基-ALPHA-D-吡喃甘露糖苷 环丙胺,1-(1-甲基-1-丙烯-1-基)- 溶剂紫9 溴化N,N,N-三乙基-2-(三苯代甲基氧代)乙铵 海涛林